Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139

Lancet

Volumn 348, Issue 9023, 1996, Pages 296-300

  Khan, Wasif Ali ^a   Bennish, Michael L ^b   Seas, Carlos ^a,c   Khan, Eradul Haq ^a   Ronan, Anne ^a,d   Dhar, Ujjwal ^a   Busch, Wilhelm ^e   Salam, Mohammed Abdus ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d ROYAL NEWCASTLE HOSPITAL   (Australia)

^e BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; FECES CULTURE; FLUID INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIBRIO CHOLERAE;

EID: 0030567832     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)01180-4     Document Type: Article

References (25)

1. Anonymous. Cholera in 1944: part 1. Wkly Epidemiol Rec 1995; 70: 201-08.
2. Bennish ML. Cholera: pathophysiology, clinical features, and treatment. In: Wachsmuth IK, Blake PA, Olsvik Ø, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology, 1994: 229-55.
3. Greenough WB III, Gordon RS, Rosenberg IS, Davies BI, Benenson AS. Tetracycline in the treatment of cholera. Lancet 1964; i: 355-57.
4. World Health Organization Programme for Control of Diarrhoeal Disease. Guildelines for cholera control. Geneva: World Health Organization, 1991. WHO/CDD/SER/80.4 REV.2 (1991).
5. Bennish ML, Levy SB. Antimicrobial resistance of enteric pathogens. In: Blaser JM, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Infections of the gastrointestinal tract. New York: Raven Press Ltd, 1995: 1499-523.
6. Yamamoto T, Nair G, Albert MJ, Parodi CC, Takeda Y. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother 1995; 39: 241-44.
7. Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? Lancet 1995; 345: 339-44.
8. DuPont HL Diarrhoeal disease: current concepts and future challenges: antimicrobial therapy and prophylaxis. Trans R Soc Trop Med Hyg. 87((suppl 3)):1993;31-34.
9. Bhattacharya SK, Bhattacharya MK, Dutta P, et al. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrob Agents Chemother 1990; 34: 939-46.
10. Gottuzo E, Seas C, Echevarría J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 1995; 20: 1485-90.
11. Khan WA, Begum M, Salam MA, Bardhan PK, Islam MR, Mahalanabis D. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans R Soc Trop Med Hyg 1995; 89: 103-06.
12. Salam MA, Bennish ML. Therapy for shigellosis: 1. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988; 113: 901-07.
13. Scholl H, Schmidt K, Weber B. Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. J Chromatogr 1987; 416: 321-30.
14. Hewitt W, Vincent S. Theory and application of microbiologic assay. San Diego: Academic Press Inc, 1989.
15. Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 1990; 300: 1619-21.
16. De S, Chaudhuri A, Dutta D, De SP, Pal SC. Doxycycline in the treatment of cholera. Bull World Health Organ 1976; 54: 177-79.
17. Sack DA, Islam S, Rabbani H, Islam A. Single-dose doxycycline for cholera. Antimicrob Agents Chemother 1978; 14: 462-64.
18. Islam MR. Single dose tetracycline in cholera. Gut 1987; 28: 1029-32.
19. Rabbani GH, Islam MR, Butler T, Shahrier M, Alam K. Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial. Antimicrob Agents Chemother 1989; 33: 1447-50.
20. Mhalu FS, Mtango FDE, Msengi AE. Hospital outbreaks of cholera transmitted through close person-to-person contact. Lancet 1984; ii: 82-84.
21. Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8 (suppl 2): S172-81.
22. DePaola A, Flynn PA, McPherson RM, Levy SB. Phenotypic and genotypic characterization of tetracycline- and oxytetracycline-resistant Aeromonas hydrophila from cultured channel catfish (Ictalurus punctatus) and their environments. Appl Environ Microbiol; 1988; 54: 1861-63.
23. Rabbani GH, Butler T, Shahrier M, Mazumder R, Islam MR. Efficacy of single dose of furazolidone for treatment of cholera in children. Antimicrob Agents Chemother 1991; 35: 1864-67.
24. Dhar U, Bennish ML, Khan WA, et al. Clinical features, antimicrobial susceptibility, and toxin production in Vibrio cholerae O139 infection: comparison with Vibrio cholerae O1 infection. Trans R Soc Trop Med Hyg 1996 (in press).
25. Schaad UB, Salam MA, Aujard Yet al. Use of fluroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 14:1995;1-9.